American Journal of Ophthalmology
Volume 150, Issue 1 , Pages 122-127.e5 , July 2010

Multicenter Clinical Evaluation of Bepotastine Besilate Ophthalmic Solutions 1.0% and 1.5% to Treat Allergic Conjunctivitis

  • Thomas T. Macejko

      Affiliations

    • Eye Care Associates of Greater Cincinnati, Inc, Fairfield, Ohio
    • ,
  • Mark T. Bergmann

      Affiliations

    • Eye Care Associates of Greater Cincinnati, Inc, Cincinnati, Ohio
    • ,
  • Jon I. Williams

      Affiliations

    • ISTA Pharmaceuticals, Inc, Irvine, California
    • Corresponding Author InformationInquiries to Jon I. Williams, ISTA Pharmaceuticals, Inc, 15295 Alton Parkway, Irvine, CA 92618
    • ,
  • James A. Gow

      Affiliations

    • ISTA Pharmaceuticals, Inc, Irvine, California
    • ,
  • Paul J. Gomes

      Affiliations

    • Ora, Inc, Andover, Massachusetts
    • ,
  • Timothy R. McNamara

      Affiliations

    • ISTA Pharmaceuticals, Inc, Irvine, California
    • ,
  • Mark B. Abelson

      Affiliations

    • Ora, Inc, Andover, Massachusetts
    • Schepens Eye Research Institute, Boston, Massachusetts
    • Harvard Medical School, Boston, Massachusetts
    • ,
  • Bepotastine Besilate Ophthalmic Solutions Clinical Study Group

,Accepted 3 February 2010.

References 

  1. Abelson MB, Smith L, Chapin M. Ocular allergic disease: mechanisms, disease sub-types, treatment. Ocul Surf. 2003;1(3):127–149
  2. von Mutius E, Martinez FD, Fritzsch C, Nicolai T, Roell G, Thiemann HH. Prevalence of asthma and atopy in two areas of West and East Germany. Am J Respir Crit Care Med. 1994;149(2 pt 1):358–364
  3. Abelson MB, George MA, Garofalo C. Differential diagnosis of ocular allergic disorders. Ann Allergy. 1993;70(2):95–109
  4. Katelaris CH. Allergic rhinoconjunctivitis—an overview. Acta Ophthalmol Scand. 2000;230(suppl):66–68
  5. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115(1):118–122
  6. Bonini S, Bonini S, Vecchione A, Naim DM, Allansmith MR, Balsano F. Inflammatory changes in conjunctival scrapings after allergen provocation in humans. J Allergy Clin Immunol. 1988;82(3 pt 1):462–469
  7. Barnes PJ. Pathophysiology of allergic inflammation. In:  Adkinson NF,  Bochner BS,  Busse WW,  Holgate ST,  Lemanske RF,  Simons FE editor. Middleton's Allergy: Principles & Practice. 7th ed.. Philadelphia: Elsevier Mosby; 2009;p. 455–472
  8. Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med. 1994;330(23):1663–1670
  9. Simons FE. Advances in H1-antihistamines. N Engl J Med. 2004;351(21):2203–2217
  10. Kato M, Nishida A, Aga Y. Pharmacokinetic and pharmacodynamic evaluation of the central effect of the novel antiallergic agent bepotastine besilate. Arzneimittelforschung. 1997;47(10):1116–1124
  11. Sakai A, Kikuchi M, Yato N, Kikkawa S, Saito N, Narita H. Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice. Arzneimittelforschung. 1997;47(8):954–958
  12. Kaminuma O, Ogawa K, Kikkawa H, Kikuchi M, Naito K, Ikezawa K. A novel anti-allergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells. Biol Pharm Bull. 1998;21(4):411–413
  13. Ishibashi Y, Harada S, Niimura M. Long term treatment of TAU-284 (betotastine besilate) on chronic urticaria [in Japanese]. J Clin Ther Med. 1997;13(5):1337–1359
  14. Ishibashi Y, Harada S, Niimura M, Kawashima M, Yamamoto S, Yoshida H. Clinical evaluation of TAU-284 (betotastine besilate) on eczema/dermatitis, prurigo, and pruritus cutaneous [in Japanese]. J Clin Ther Med. 1997;13(5):1383–1400
  15. Baba S, Takasaki T, Baba K, et al. Late phase II clinical study of TAU-284 for perennial allergic rhinitis—dose finding study by the double-blind method [in Japanese]. J Clin Ther Med. 1997;13(5):1259–1286
  16. Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther. 2009;31(9):1908–1921
  17. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol. 1998;81(3):211–218
  18. Shulman DG, Amdahl L, Washington C, Graves A. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents. Clin Ther. 2003;25(4):1096–1106
  19. Reigelman RK. Studying a study and testing a test. In: Philadelphia: Lippincott Williams & Wilkins; 2005;p. 336
  20. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol. 1998;125(6):797–804
  21. Abelson MB, Chapin MJ, Kapik BM, Shams NB. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. Arch Ophthalmol. 2003;121(5):626–630
  22. Abelson MB, Gomes P, Crampton HJ, Schiffman RM, Bradford RR, Whitcup SM. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther. 2004;26(1):35–47
  23. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge (A clinical approach to studying allergic conjunctivitis). Arch Ophthalmol. 1990;108(1):84–88

 Supplemental Material available at AJO.com.

PII: S0002-9394(10)00113-3

doi: 10.1016/j.ajo.2010.02.007

American Journal of Ophthalmology
Volume 150, Issue 1 , Pages 122-127.e5 , July 2010

Article Tools

* Image Usage & Resolution